{"id":53332,"date":"2026-01-08T13:20:57","date_gmt":"2026-01-08T05:20:57","guid":{"rendered":"https:\/\/flcube.com\/?p=53332"},"modified":"2026-01-08T13:20:58","modified_gmt":"2026-01-08T05:20:58","slug":"hutchmeds-sovleplenib-meets-phase-3-primary-endpoint-in-waiha-targets-nda-filing","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53332","title":{"rendered":"HutchMed&#8217;s Sovleplenib Meets Phase 3 Primary Endpoint in wAIHA, Targets NDA Filing"},"content":{"rendered":"\n<p><strong>HutchMed (China) Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/HCM:NASDAQ\">NASDAQ: HCM<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/0013:HKG\">HKG: 0013<\/a>) announced that the <strong>Phase\u202f3 registration part<\/strong> of the <strong>ESLIM\u201102<\/strong> clinical trial evaluating <strong>sovleplenib<\/strong>, a novel <strong>spleen tyrosine kinase (Syk) inhibitor<\/strong>, achieved its <strong>primary endpoint<\/strong> in adult patients with <strong>warm antibody autoimmune hemolytic anemia (wAIHA)<\/strong>. The trial met the <strong>durable hemoglobin (Hb) response rate<\/strong> within weeks\u202f5\u201124, positioning sovleplenib as a <strong>potential first\u2011in\u2011class therapy<\/strong> in a market with no approved Syk inhibitor.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-phase-3-trial-results-summary\">Phase\u202f3 Trial Results Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug<\/strong><\/td><td>Sovleplenib (Syk inhibitor)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>HutchMed (China) Ltd (HCM\/0013)<\/td><\/tr><tr><td><strong>Trial<\/strong><\/td><td>ESLIM\u201102 (Phase\u202f3 registration part)<\/td><\/tr><tr><td><strong>Design<\/strong><\/td><td>Randomized, double\u2011blind, placebo\u2011controlled China Phase\u202fII\/III<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>Primary or secondary wAIHA, relapsed\/refractory to \u22651 prior line<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Durable Hb response rate (weeks\u202f5\u201124) \u2013 <strong>ACHIEVED<\/strong><\/td><\/tr><tr><td><strong>Phase\u202f2 Results<\/strong><\/td><td>ORR 43.8% vs. 0% (placebo, first\u202f8\u202fweeks); ORR 66.7% (24\u202fweeks, including crossover)<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable, consistent with earlier studies<\/td><\/tr><tr><td><strong>Next Milestone<\/strong><\/td><td>NDA submission to NMPA planned for H1\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-disease-background-amp-market-opportunity\">Disease Background &amp; Market Opportunity<\/h2>\n\n\n\n<p><strong>Warm AIHA (wAIHA)<\/strong> is an autoimmune disorder where antibodies destroy red blood cells, causing severe anemia and transfusion dependence.<\/p>\n\n\n\n<p><strong>Epidemiology<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Incidence<\/strong>: <strong>~15,000\u201120,000<\/strong> eligible patients with relapsed\/refractory wAIHA<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: Corticosteroids (first\u2011line), rituximab (off\u2011label), no approved Syk inhibitor<\/li>\n\n\n\n<li><strong>Market Size<\/strong>: China wAIHA drug market valued at <strong>\u00a52\u20113\u202fbillion<\/strong> (2025), growing at <strong>15% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: <strong>30\u201140%<\/strong> of patients fail to respond or relapse, requiring <strong>steroid\u2011sparing alternatives<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Sovleplenib Peak Sales Potential<\/strong>: <strong>\u00a5800\u202fmillion\u20111.2\u202fbillion<\/strong> (US$110\u2011170\u202fmillion) by 2030, assuming <strong>10\u201112%<\/strong> market penetration.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>Stage (China)<\/th><th>Limitations<\/th><\/tr><\/thead><tbody><tr><td><strong>Sovleplenib<\/strong><\/td><td><strong>HutchMed<\/strong><\/td><td>Syk inhibitor<\/td><td><strong>Phase\u202f3 completed<\/strong><\/td><td>First in China<\/td><\/tr><tr><td><strong>Fostamatinib<\/strong><\/td><td>Rigel\/AstraZeneca<\/td><td>Syk inhibitor<\/td><td><strong>Not approved<\/strong><\/td><td>Limited efficacy, EU\/US only<\/td><\/tr><tr><td><strong>Rilzabrutinib<\/strong><\/td><td>Sanofi<\/td><td>BTK inhibitor<\/td><td>Phase\u202fIII<\/td><td>Different target, safety concerns<\/td><\/tr><tr><td><strong>Rituximab<\/strong><\/td><td>Roche<\/td><td>CD20 mAb<\/td><td>Off\u2011label use<\/td><td>Immunosuppression, infusion required<\/td><\/tr><tr><td><strong>Corticosteroids<\/strong><\/td><td>Generic<\/td><td>Immunosuppression<\/td><td>Standard of care<\/td><td>High toxicity, relapse risk<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>First\u2011Mover Advantage<\/strong>: Sovleplenib is <strong>12\u201118 months ahead<\/strong> of Sanofi\u2019s rilzabrutinib in China, with <strong>Breakthrough Therapy Designation<\/strong> supporting <strong>priority review<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-amp-regulatory-pathway\">Clinical Development &amp; Regulatory Pathway<\/h2>\n\n\n\n<p><strong>Phase\u202f2 Foundation<\/strong>: ESLIM\u201102\u2019s Phase\u202f2 part demonstrated <strong>robust hemoglobin improvement<\/strong> with favorable safety, justifying <strong>expedited Phase\u202f3 progression<\/strong>.<\/p>\n\n\n\n<p><strong>NDA Strategy<\/strong>: HutchMed plans submission in <strong>H1\u202f2026<\/strong>, leveraging:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Priority Review<\/strong>: BTD status reduces NMPA review timeline from <strong>200 to 130 days<\/strong><\/li>\n\n\n\n<li><strong>Real\u2011World Evidence<\/strong>: Data from <strong>Lecheng Pilot Zone<\/strong> early access program (started March\u202f2025) may supplement NDA<\/li>\n\n\n\n<li><strong>Manufacturing<\/strong>: Chengdu facility GMP\u2011certified for <strong>Syk inhibitor production<\/strong> (capacity: 200\u202fkg\/year)<\/li>\n<\/ul>\n\n\n\n<p><strong>Approval Timeline<\/strong>: Potential NMPA approval in <strong>Q1\u202f2027<\/strong>, commercial launch in <strong>H1\u202f2027<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact-amp-hutchmed-valuation\">Financial Impact &amp; HutchMed Valuation<\/h2>\n\n\n\n<p><strong>Near\u2011Term Milestones<\/strong>: NDA submission could trigger <strong>$50\u201180\u202fmillion<\/strong> in payments from <strong>existing partnerships<\/strong> (e.g., strategic investors).<\/p>\n\n\n\n<p><strong>Revenue Model<\/strong>: HutchMed retains <strong>Greater China rights<\/strong>; no ex\u2011China deal announced yet, preserving <strong>full economics<\/strong> in the <strong>\u00a52\u20113\u202fbillion<\/strong> market.<\/p>\n\n\n\n<p><strong>Stock Catalyst<\/strong>: Phase\u202f3 success <strong>derisks<\/strong> sovleplenib franchise and could drive <strong>15\u201120% upside<\/strong> in HCM shares, based on <strong>DCF valuation<\/strong> of <strong>\u00a58\u201110 per share<\/strong> for wAIHA indication alone.<\/p>\n\n\n\n<p><strong>Cash Position<\/strong>: HutchMed ended Q3\u202f2025 with <strong>$450\u202fmillion<\/strong> in cash, sufficient to fund <strong>sovleplenib registration<\/strong> and <strong>two additional Syk programs<\/strong> (LNH\u201197 for lymphoma, HUTCH\u20111402 for ITP).<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding sovleplenib\u2019s NDA submission timeline, regulatory approval probability, market penetration, and peak sales forecasts. Actual results may differ materially due to competitive dynamics, NMPA review outcomes, pricing negotiations, and potential safety signals in broader populations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that the Phase\u202f3 registration part of the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,1105,285,1104],"class_list":["post-53332","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-hkg-0013","tag-hutchmed","tag-nasdaq-hcm"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HutchMed&#039;s Sovleplenib Meets Phase 3 Primary Endpoint in wAIHA, Targets NDA Filing - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that the Phase\u202f3 registration part of the ESLIM\u201102 clinical trial evaluating sovleplenib, a novel spleen tyrosine kinase (Syk) inhibitor, achieved its primary endpoint in adult patients with warm antibody autoimmune hemolytic anemia (wAIHA). The trial met the durable hemoglobin (Hb) response rate within weeks\u202f5\u201124, positioning sovleplenib as a potential first\u2011in\u2011class therapy in a market with no approved Syk inhibitor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53332\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HutchMed&#039;s Sovleplenib Meets Phase 3 Primary Endpoint in wAIHA, Targets NDA Filing\" \/>\n<meta property=\"og:description\" content=\"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that the Phase\u202f3 registration part of the ESLIM\u201102 clinical trial evaluating sovleplenib, a novel spleen tyrosine kinase (Syk) inhibitor, achieved its primary endpoint in adult patients with warm antibody autoimmune hemolytic anemia (wAIHA). The trial met the durable hemoglobin (Hb) response rate within weeks\u202f5\u201124, positioning sovleplenib as a potential first\u2011in\u2011class therapy in a market with no approved Syk inhibitor.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53332\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-08T05:20:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-08T05:20:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53332#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53332\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HutchMed&#8217;s Sovleplenib Meets Phase 3 Primary Endpoint in wAIHA, Targets NDA Filing\",\"datePublished\":\"2026-01-08T05:20:57+00:00\",\"dateModified\":\"2026-01-08T05:20:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53332\"},\"wordCount\":537,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"HKG: 0013\",\"HutchMed\",\"NASDAQ: HCM\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53332#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53332\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53332\",\"name\":\"HutchMed's Sovleplenib Meets Phase 3 Primary Endpoint in wAIHA, Targets NDA Filing - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-08T05:20:57+00:00\",\"dateModified\":\"2026-01-08T05:20:58+00:00\",\"description\":\"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that the Phase\u202f3 registration part of the ESLIM\u201102 clinical trial evaluating sovleplenib, a novel spleen tyrosine kinase (Syk) inhibitor, achieved its primary endpoint in adult patients with warm antibody autoimmune hemolytic anemia (wAIHA). The trial met the durable hemoglobin (Hb) response rate within weeks\u202f5\u201124, positioning sovleplenib as a potential first\u2011in\u2011class therapy in a market with no approved Syk inhibitor.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53332#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53332\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53332#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HutchMed&#8217;s Sovleplenib Meets Phase 3 Primary Endpoint in wAIHA, Targets NDA Filing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HutchMed's Sovleplenib Meets Phase 3 Primary Endpoint in wAIHA, Targets NDA Filing - Insight, China&#039;s Pharmaceutical Industry","description":"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that the Phase\u202f3 registration part of the ESLIM\u201102 clinical trial evaluating sovleplenib, a novel spleen tyrosine kinase (Syk) inhibitor, achieved its primary endpoint in adult patients with warm antibody autoimmune hemolytic anemia (wAIHA). The trial met the durable hemoglobin (Hb) response rate within weeks\u202f5\u201124, positioning sovleplenib as a potential first\u2011in\u2011class therapy in a market with no approved Syk inhibitor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53332","og_locale":"en_US","og_type":"article","og_title":"HutchMed's Sovleplenib Meets Phase 3 Primary Endpoint in wAIHA, Targets NDA Filing","og_description":"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that the Phase\u202f3 registration part of the ESLIM\u201102 clinical trial evaluating sovleplenib, a novel spleen tyrosine kinase (Syk) inhibitor, achieved its primary endpoint in adult patients with warm antibody autoimmune hemolytic anemia (wAIHA). The trial met the durable hemoglobin (Hb) response rate within weeks\u202f5\u201124, positioning sovleplenib as a potential first\u2011in\u2011class therapy in a market with no approved Syk inhibitor.","og_url":"https:\/\/flcube.com\/?p=53332","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-08T05:20:57+00:00","article_modified_time":"2026-01-08T05:20:58+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53332#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53332"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HutchMed&#8217;s Sovleplenib Meets Phase 3 Primary Endpoint in wAIHA, Targets NDA Filing","datePublished":"2026-01-08T05:20:57+00:00","dateModified":"2026-01-08T05:20:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53332"},"wordCount":537,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","HKG: 0013","HutchMed","NASDAQ: HCM"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53332#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53332","url":"https:\/\/flcube.com\/?p=53332","name":"HutchMed's Sovleplenib Meets Phase 3 Primary Endpoint in wAIHA, Targets NDA Filing - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-08T05:20:57+00:00","dateModified":"2026-01-08T05:20:58+00:00","description":"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that the Phase\u202f3 registration part of the ESLIM\u201102 clinical trial evaluating sovleplenib, a novel spleen tyrosine kinase (Syk) inhibitor, achieved its primary endpoint in adult patients with warm antibody autoimmune hemolytic anemia (wAIHA). The trial met the durable hemoglobin (Hb) response rate within weeks\u202f5\u201124, positioning sovleplenib as a potential first\u2011in\u2011class therapy in a market with no approved Syk inhibitor.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53332#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53332"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53332#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HutchMed&#8217;s Sovleplenib Meets Phase 3 Primary Endpoint in wAIHA, Targets NDA Filing"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53332"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53332\/revisions"}],"predecessor-version":[{"id":53334,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53332\/revisions\/53334"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}